As mechanism of action, JAK3 inhibitors inhibit NKTCL cell growth in an EZH2 phosphorylation-dependent manner, which functions as a transcriptional activator of NKTCL. Here, EZH2 is linked to extranodal nasal NK/T cell lymphoma.